Article Details

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Retrieved on: 2025-10-15 12:29:55

Tags for this article:

Click the tags to see associated articles and topics

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio. View article details on hiswai:

Excerpt

ADCs harness the specificity of monoclonal antibodies and the potency of cytotoxic agents – in this case a derivative of exatecan – to selectively ...

Article found on: www.theglobeandmail.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo